CD8A and non-small cell lung carcinoma: For DSP application in clinical research, Blank et al. have explained the combination immunotherapy superiority for melanoma treatment [63], and later multiple biomarkers (CD3, CD4, CD8, CD20, and PD-L1), which could be potentially available for predicting response to immune therapy in non–small cell lung cancer (NSCLC), were evaluated [64].